Home/Filings/4/0001209191-21-042752
4//SEC Filing

BAYER AKTIENGESELLSCHAFT 4

Accession 0001209191-21-042752

CIK 0001850119other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 4:41 PM ET

Size

14.9 KB

Accession

0001209191-21-042752

Insider Transaction Report

Form 4
Period: 2021-06-22
Transactions
  • Conversion

    Common Stock

    2021-06-22+1,535,23811,925,838 total
  • Conversion

    Series B Preferred Stock

    2021-06-2226,143,7900 total
    Common Stock (10,390,600 underlying)
  • Conversion

    Common Stock

    2021-06-22+10,390,60010,390,600 total
  • Purchase

    Common Stock

    2021-06-22$20.00/sh+750,000$15,000,00012,675,838 total
  • Conversion

    Series C Preferred Stock

    2021-06-223,862,8130 total
    Common Stock (1,535,238 underlying)
Transactions
  • Conversion

    Series B Preferred Stock

    2021-06-2226,143,7900 total
    Common Stock (10,390,600 underlying)
  • Purchase

    Common Stock

    2021-06-22$20.00/sh+750,000$15,000,00012,675,838 total
  • Conversion

    Common Stock

    2021-06-22+10,390,60010,390,600 total
  • Conversion

    Series C Preferred Stock

    2021-06-223,862,8130 total
    Common Stock (1,535,238 underlying)
  • Conversion

    Common Stock

    2021-06-22+1,535,23811,925,838 total
Footnotes (3)
  • [F1]Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.
  • [F2]The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
  • [F3]Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.

Issuer

Century Therapeutics, Inc.

CIK 0001850119

Entity typeother

Related Parties

1
  • filerCIK 0001144145

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:41 PM ET
Size
14.9 KB